Sugi Predict

Sugi Predict / Targets / TLR9

TLR9

Toll-like receptor 9 · Q9NR96 · TLR9 on Sugi Atlas →

111,976 patent compounds predicted against TLR9, 61,134 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL182816 SCHEMBL182816 0.60 5/20
SCHEMBL255093 SCHEMBL255093 0.44 5/20
SCHEMBL182950 SCHEMBL182950 0.58 4/20
SCHEMBL182675 SCHEMBL182675 0.45 4/20
SCHEMBL183052 SCHEMBL183052 0.71 3/20
SCHEMBL142504 SCHEMBL142504 0.70 3/20
SCHEMBL141767 SCHEMBL141767 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL193439) 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL193440) 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL193862) 0.50 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL193863) 0.50 3/20
SCHEMBL138553 SCHEMBL138553 0.48 3/20
SCHEMBL199299 SCHEMBL199299 0.48 3/20
SCHEMBL182970 SCHEMBL182970 0.47 3/20
SCHEMBL44174 SCHEMBL44174 0.41 3/20
SCHEMBL215873 SCHEMBL215873 0.41 3/20
SCHEMBL63292 SCHEMBL63292 0.36 3/20
SCHEMBL233141 SCHEMBL233141 0.32 3/20
SCHEMBL121404 SCHEMBL121404 1.00 2/20
SCHEMBL58050 SCHEMBL58050 0.70 2/20

Clinical trials — most relevant to TLR9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study PHASE4COMPLETED
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy PHASE4UNKNOWN
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar PHASE2/PHASE3UNKNOWN
A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy PHASE2COMPLETED
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL PHASE2COMPLETED
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma PHASE2RECRUITING
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients PHASE1/PHASE2COMPLETED
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors PHASE2COMPLETED
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients PHASE1/PHASE2COMPLETED
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia PHASE2COMPLETED
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors PHASE1COMPLETED
The Effects of GLA on Human Volunteers PHASE1COMPLETED
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers PHASE1COMPLETED
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours PHASE1RECRUITING
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer EARLY_PHASE1COMPLETED
Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU) nanUNKNOWN
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients nanUNKNOWN
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
TLR 9 (rs352140) Gene Polymorphism in Helicobacter Pylori Infection nanCOMPLETED
Ccf mtDNA as a Neurodegenerative Biomarker nanUNKNOWN
Bacteremia in Intensive Care Unit (ICU) nanUNKNOWN
TLR4 Polymorphisms and Risk of Skin Cancer nanCOMPLETED
Neuro-Immune Interactions in the Gut nanCOMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus nanUNKNOWN
Extracorporeal cfDNA Removal in Septic Shock Patients With Elevated DNA Levels nanNOT_YET_RECRUITING
MitoQ to Improve Vascular Funciton in Preeclampsia nanRECRUITING
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 nanCOMPLETED
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection nanCOMPLETED
The Suppression of Toll Like Receptors by Insulin nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TLR9 binder may also engage these)

ProteinNameSimilarity
Q2EEY0 — 1.000 Q2EEY0 →
Q5I2M3 — 1.000 Q5I2M3 →
Q5I2M4 — 1.000 Q5I2M4 →
Q5I2M7 — 1.000 Q5I2M7 →
Q5I2M8 — 0.999 Q5I2M8 →
Q5I2M5 — 0.999 Q5I2M5 →
G3XA59 — 0.992 G3XA59 →
Q9EQU3 — 0.991 Q9EQU3 →
Q6UY18 — 0.989 Q6UY18 →
Q5RF01 — 0.985 Q5RF01 →
Q149C3 — 0.984 Q149C3 →
Q9JLF7 — 0.982 Q9JLF7 →
Q8C2S7 — 0.982 Q8C2S7 →
Q14392 — 0.981 Q14392 →
Q8CBR6 — 0.981 Q8CBR6 →
Q8WUA8 — 0.981 Q8WUA8 →
O08770 — 0.980 O08770 →
Q86YC3 — 0.980 Q86YC3 →
P40197 — 0.980 P40197 →
Q9DBB9 — 0.980 Q9DBB9 →
Q5NVQ6 — 0.980 Q5NVQ6 →
Q6QMY6 — 0.979 Q6QMY6 →
Q9HBX8 — 0.979 Q9HBX8 →
P0DM44 — 0.979 P0DM44 →
Q6QNU9 — 0.978 Q6QNU9 →
Q86WK7 — 0.978 Q86WK7 →
F1MT22 — 0.978 F1MT22 →
P22792 — 0.977 P22792 →
Q3ZBI5 — 0.977 Q3ZBI5 →
O14498 — 0.977 O14498 →